AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Capsaicin in Digital Osteoarthritis Versus Control

RecruitingPhase 4Ages 18 Years - anyAllUniversity Hospital, Clermont-Ferrand
💬

In plain words

What the trial is, and whether it could suit you

The objective of this multicentric, randomized controlled double-blind clinical trial is to demonstrate the efficacy of transdermal application of capsaicin in patients with painful digital osteoarthritis with a neuropathic pain component. Participants will receive either a transdermal patch of capsaicin 179 mg (8%) or the control treatment (capsaicin 0.04%). Researchers will compare the intensity of pain in the fingers at day 60 in the capsaicin 8% group versus capsaicin 0.04% (control arm)

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of digital osteoarthritis fulfilling the American College of Rheumatology criteria; * Presence of finger pain of ≥ 40 mm on a visual analogue scale (VAS); * Presence of finger pain with a neuropathic pain component (DN4 score ≥ 4/10) * Inadequate response, adverse reactions, and/or contraindications to conventional analgesics and NSAIDs; Exclusion Criteria: * Patient with isolated rhizarthrosis; * Patient with other joint disease affecting the fingers (gout, chondrocalcinosis, RA, spondyloarthritis, psoriatic arthritis); * Patient with upper extremity pain syndrome that may interfere with the assessment of finger pain; * Patient with another pathology responsible for neuropathic hand pain (carpal tunnel syndrome, diabetic neuropathy, Guyon's tunnel syndrome, cervicobrachial neuralgia, brachial plexitis); * Patient with skin lesions on the fingers (psoriasis, wounds, chronic ulcers, eczema, shingles, dermatitis); * Patient with poorly controlled high blood pressure; * Patient with hypersensitivity to capsaicin; * Patient who had 8% capsaicin patch use in the year prior to the study; * Patient who has received intramuscular, intra-articular or intravenous corticosteroid therapy, another disease-modifying anti-rheumatic therapy (methotrexate, salazopyrine) or an intra-articular injection into the joints of the fingers within the previous 3 months; * Patient wearing wrist or finger orthoses in the previous month; * Patient with fibromyalgia;
💊

What it tests

  • Capsaicin 179 Mg Cutaneous Patch
  • Capsaicine low dose 0.04 %
📍

Where

4 sites
CHU de Clermont-Ferrand
Clermont-Ferrand, France
HCL Hôpital Edouard Herriot
Lyon, France
AP-HP Hôpital Saint-Antoine
Paris, France
CHU de Saint-Etienne
Saint-Etienne, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy